The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Announced promising safety and positive biomarker data from Cohort 2 (5mg BID) of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients demonstrating dose dependent ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

A new form of diagnostic imaging is changing how doctors see and treat lung conditions like cystic fibrosis. For as long as ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

We are thrilled to welcome Heather to the Avalyn team and to her new role as Board Chair,” said Lyn Baranowski, chief executive officer of Avalyn. “As we look ahead, we are excited to tap into Heather ...